Post GLP Guide: Comprehensive Review of GLP Peptides

Research Library

Post GLP Guide: Comprehensive Review of GLP Peptides

Explore the differences between GLP-1, GLP-2, and the less-characterized GLP-3, including their origins in proglucagon, receptor signaling, roles in glucose regulation, appetite, intestinal growth, barrier integrity, and current research limitations.

ECP Research Team 10 min read
In this article8 sections
Key takeaways

GLP-1

GLP-2

Oxyntomodulin

Research use onlyEducational content for laboratory and research applications. Not medical or dosing advice.

The glucagon-like peptides are a group of signaling molecules produced through the processing of proglucagon, a larger precursor protein encoded by the GCG gene.

The best-characterized members of this family are GLP-1 and GLP-2. GLP-1 is closely associated with glucose regulation, insulin secretion, appetite, and metabolic signaling, while GLP-2 is studied primarily for its effects on intestinal growth, barrier integrity, nutrient absorption, and gastrointestinal adaptation.

The term GLP-3 is sometimes used in discussions of additional glucagon-like or glicentin-related sequences produced during proglucagon processing. However, this area is much less clearly defined than GLP-1 and GLP-2, and its receptor biology and physiological significance remain uncertain.

This article reviews the origins, proposed mechanisms, and major research applications of GLP-1, GLP-2, and the less-characterized GLP-3 concept.

For research use only. Not intended for human or veterinary use. Research preparations are distinct from approved pharmaceutical products.

Proglucagon: The Common Precursor

GLP-1 and GLP-2 originate from the same precursor protein: proglucagon.

The biological products formed from proglucagon depend on the tissue in which it is processed and which prohormone-converting enzymes are present.

Processing in the pancreas

In pancreatic alpha cells, prohormone convertase 2 primarily processes proglucagon into glucagon-related products.

Glucagon helps regulate blood glucose by increasing hepatic glucose production during fasting or low-glucose conditions.

Processing in the intestine and brain

In intestinal L-cells and certain neurons in the brainstem, prohormone convertase 1/3 produces a different group of peptides, including:

  • GLP-1
  • GLP-2
  • Oxyntomodulin
  • Glicentin
  • Other related peptide fragments

This tissue-specific processing allows one precursor protein to generate hormones with very different biological roles.

GLP-1

What Is GLP-1?

GLP-1 stands for glucagon-like peptide-1.

It is released primarily from intestinal L-cells after nutrient intake, particularly in response to carbohydrates and fats. GLP-1 is also produced by specialized neurons in the brainstem.

Native GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4, commonly abbreviated as DPP-4. Its short biological half-life limits the duration of its natural signaling.

Long-acting pharmaceutical GLP-1 receptor agonists were developed to resist degradation and provide prolonged receptor activation. These drugs should not be confused with native GLP-1 research preparations.

GLP-1 Receptor Signaling

GLP-1 binds the GLP-1 receptor, a class B G-protein-coupled receptor.

The receptor is expressed in several tissues, including:

  • Pancreatic beta cells
  • Gastrointestinal tissues
  • Brain and brainstem
  • Cardiovascular tissues
  • Kidneys
  • Lungs

GLP-1 receptor activation primarily stimulates the Gαs pathway, increasing adenylyl cyclase activity and intracellular cyclic AMP.

This can activate:

  • Protein kinase A
  • Epac2
  • Calcium-dependent signaling
  • Insulin-secretory pathways
  • Transcriptional responses

Glucose-Dependent Insulin Secretion

One of GLP-1’s most important functions is enhancement of glucose-stimulated insulin secretion.

When glucose levels rise after a meal, GLP-1 receptor signaling increases the ability of pancreatic beta cells to release insulin.

This is part of the incretin effect, in which oral glucose produces a greater insulin response than the same amount of glucose delivered intravenously.

The glucose-dependent nature of this activity is important because the insulin-enhancing effect becomes weaker when glucose levels are not elevated.

Glucagon Regulation

GLP-1 also contributes to suppression of glucagon during the post-meal period.

Glucagon normally raises blood glucose by signaling the liver to release stored glucose and increase glucose production.

Postprandial glucagon suppression helps prevent excessive hepatic glucose output while nutrients are being absorbed.

This effect may involve direct and indirect signaling, including interactions with pancreatic somatostatin pathways.

Gastric Emptying

GLP-1 can slow gastric emptying, reducing the rate at which food leaves the stomach and enters the small intestine.

This may influence:

  • Post-meal glucose exposure
  • Nutrient absorption rate
  • Gastric fullness
  • Meal size
  • Satiety

The contribution of delayed gastric emptying may change over time and can differ between native GLP-1 and long-acting receptor agonists.

Central Appetite Signaling

GLP-1 receptors are present in brain regions involved in appetite and energy balance.

These include:

  • Hypothalamic nuclei
  • Area postrema
  • Nucleus tractus solitarius
  • Reward-related neural pathways

Activation of these systems can reduce food intake and increase satiety.

This central signaling is a major reason GLP-1 receptor biology is widely studied in obesity and metabolic research.

Beta-Cell Biology

Preclinical studies have examined whether GLP-1 receptor activation influences:

  • Beta-cell survival
  • Beta-cell proliferation
  • Insulin synthesis
  • Cellular stress responses
  • Apoptosis
  • Maintenance of functional beta-cell mass

These findings are strongest in experimental models. The degree to which beta-cell regeneration occurs in humans remains uncertain.

Cardiovascular Research

GLP-1 receptor signaling has also been studied in cardiovascular models.

Research areas include:

  • Endothelial function
  • Myocardial metabolism
  • Ischemic injury
  • Inflammatory signaling
  • Atherosclerosis
  • Blood-pressure regulation

Clinical cardiovascular benefits have been observed with several approved GLP-1 receptor agonists, although those outcomes should not be attributed automatically to native research GLP-1 preparations.

GLP-1 Research Applications

GLP-1 research commonly includes:

  • Type 2 diabetes models
  • Incretin physiology
  • Insulin secretion
  • Pancreatic beta-cell biology
  • Appetite regulation
  • Obesity research
  • Gastric-emptying studies
  • Cardiovascular metabolism
  • Receptor pharmacology
  • Neuroprotection research

Native GLP-1 is especially useful for studying receptor biology without the prolonged pharmacokinetic effects of modified drug analogs.

GLP-2

What Is GLP-2?

GLP-2 stands for glucagon-like peptide-2.

It is a 33-amino-acid peptide released from intestinal L-cells alongside GLP-1 in response to nutrient intake.

Unlike GLP-1, GLP-2 is studied primarily for its actions within the gastrointestinal system rather than for direct glucose-lowering or appetite effects.

Native GLP-2 is also degraded by DPP-4, giving it a relatively short duration of activity.

GLP-2 Receptor Signaling

GLP-2 binds the GLP-2 receptor, another class B G-protein-coupled receptor.

GLP-2 receptors are expressed in gastrointestinal cell populations such as:

  • Enteroendocrine cells
  • Subepithelial myofibroblasts
  • Enteric neurons
  • Other supportive intestinal cells

GLP-2 does not appear to act primarily through direct receptor activation on mature intestinal absorptive cells. Instead, many of its effects may be mediated through secondary growth factors and neural signaling.

Intestinal Growth and Adaptation

GLP-2 is one of the most important peptide signals studied in intestinal adaptation.

Research has examined its influence on:

  • Crypt-cell proliferation
  • Villus height
  • Mucosal thickness
  • Intestinal surface area
  • Epithelial-cell survival
  • Gut adaptation following resection

By increasing functional mucosal tissue, GLP-2 may improve the intestine’s ability to absorb nutrients and fluids in experimental models.

Intestinal Barrier Integrity

The intestinal barrier regulates what passes between the gut lumen and the circulation.

Disruption of this barrier can contribute to:

  • Increased permeability
  • Bacterial translocation
  • Endotoxin exposure
  • Mucosal inflammation
  • Systemic immune activation

GLP-2 has been studied for potential effects on tight-junction organization and epithelial integrity.

Researchers have examined changes in proteins such as:

  • Occludin
  • Claudins
  • ZO-1

These pathways make GLP-2 relevant to inflammatory bowel, critical-illness, and intestinal-injury research.

Nutrient Absorption

GLP-2 may improve absorptive capacity through increases in intestinal surface area and changes in nutrient-transporter expression.

Research has examined its effects on:

  • Glucose transport
  • Amino-acid absorption
  • Lipid absorption
  • Electrolyte transport
  • Fluid balance

Transporters of interest include SGLT1 and GLUT2, although the exact response depends on the model and physiological state.

Mesenteric Blood Flow

GLP-2 has been associated with increased blood flow to the intestine following nutrient intake.

Improved mesenteric circulation may help support:

  • Nutrient delivery
  • Oxygenation
  • Mucosal growth
  • Postprandial absorption
  • Intestinal recovery

This vascular effect contributes to GLP-2’s broader gastrointestinal research profile.

GLP-2 and Bone Metabolism

GLP-2 has also been investigated in relation to post-meal changes in bone turnover.

Some studies suggest that GLP-2 signaling may reduce bone resorption following food intake.

This has led to research involving:

  • Osteoclast activity
  • Postprandial bone metabolism
  • Bone-turnover markers
  • Osteoporosis-related models
  • Gut-bone signaling

The mechanisms are less established than the intestinal effects.

GLP-2 Research Applications

GLP-2 research commonly includes:

  • Short bowel syndrome models
  • Intestinal adaptation
  • Intestinal barrier function
  • Inflammatory bowel disease
  • Mucosal injury
  • Nutrient absorption
  • Mesenteric circulation
  • Gut microbiome interactions
  • Bone-turnover research
  • GLP-2 receptor pharmacology

A DPP-4-resistant GLP-2 analog is used clinically for short bowel syndrome, but research GLP-2 preparations are not equivalent to the approved pharmaceutical formulation.

GLP-3

What Does GLP-3 Refer To?

The term GLP-3 is considerably less established than GLP-1 or GLP-2.

It has been used in some contexts to describe an additional glucagon-like sequence or a peptide related to the glicentin region of proglucagon. However, GLP-3 does not have the same clearly defined physiological status, receptor system, or established nomenclature as GLP-1 and GLP-2.

This distinction is important because the term may be used inconsistently across research catalogs or secondary sources.

Current Research Status

Potential GLP-3-related research areas include:

  • Proglucagon processing
  • Glicentin-related peptide biology
  • Gastrointestinal motility
  • Pancreatic signaling
  • Nutrient sensing
  • Incretin biology
  • Receptor discovery

However, the source material does not establish a confirmed GLP-3 receptor or a clearly validated physiological mechanism comparable to GLP-1R or GLP-2R.

Claims about GLP-3 should therefore be framed as investigational.

Glicentin is a larger proglucagon-derived peptide released from intestinal L-cells.

It contains glucagon-related sequences and has been studied for possible effects on gastrointestinal activity, metabolism, and nutrient response.

Because nomenclature around lesser-characterized proglucagon fragments can vary, researchers should verify:

  • Exact amino-acid sequence
  • Source of the peptide
  • Analytical identity
  • Proposed receptor
  • Whether the material is truly GLP-3, GRPP, glicentin, or another fragment

The name alone may not be sufficient to define the biological compound.

GLP-1, GLP-2, and GLP-3 Comparison

FeatureGLP-1GLP-2GLP-3
Primary sourceIntestinal L-cells and brainstem neuronsIntestinal L-cellsDescribed as a less-characterized proglucagon-related peptide
Established receptorGLP-1RGLP-2RNot clearly established
Main research focusInsulin, glucose, appetite, metabolismIntestinal growth and barrier functionProglucagon and receptor-discovery research
DPP-4 sensitivityYesYesUncertain and sequence-dependent
Major physiological roleIncretin and satiety signalingIntestinal adaptationNot fully defined
Approved related drug classMultiple GLP-1 receptor agonistsGLP-2 analog for short bowel syndromeNone
Evidence baseExtensiveSubstantialLimited

The Incretin Effect

The incretin effect describes the greater insulin response produced by oral glucose compared with intravenous glucose at the same blood glucose concentration.

The two main incretin hormones are:

  • GLP-1
  • GIP, or glucose-dependent insulinotropic polypeptide

In type 2 diabetes, the incretin response is often reduced or altered.

This has made GLP-1 receptor signaling a major focus of diabetes research.

GLP-2 is not considered a major insulinotropic incretin in the same way, but it is released alongside GLP-1 and contributes to the gastrointestinal response to feeding.

Coordinated GLP-1 and GLP-2 Signaling

GLP-1 and GLP-2 are co-secreted from intestinal L-cells after nutrient intake.

Their combined release coordinates different aspects of the post-meal response:

GLP-1

Primarily influences:

  • Insulin secretion
  • Glucagon suppression
  • Appetite
  • Gastric emptying
  • Glucose regulation

GLP-2

Primarily influences:

  • Intestinal growth
  • Barrier integrity
  • Nutrient absorption
  • Mesenteric blood flow
  • Mucosal adaptation

Studying both peptides together allows researchers to examine how metabolic and gastrointestinal signals are integrated after feeding.

Native Peptides vs. Pharmaceutical Analogs

Native GLP peptides differ substantially from long-acting pharmaceutical receptor agonists.

Approved or investigational analogs may include structural changes that:

  • Resist DPP-4 degradation
  • Increase albumin binding
  • Extend half-life
  • Modify receptor potency
  • Alter tissue exposure
  • Support weekly or daily administration

Native peptide experiments are often useful for studying natural receptor signaling, while analog studies focus more on prolonged pharmacological activation.

Findings from one type should not automatically be generalized to the other.

Laboratory Quality Considerations

Researchers working with GLP-family peptides should verify:

  • Exact amino-acid sequence
  • Peptide identity
  • HPLC purity
  • Mass-spectrometry confirmation
  • Counterion or salt form
  • DPP-4 susceptibility
  • Recommended solvent
  • Solubility
  • Storage conditions
  • Light sensitivity
  • Freeze-thaw stability

For a peptide described as GLP-3, sequence confirmation is especially important because the terminology is not as standardized.

Stability and Experimental Design

Native GLP-1 and GLP-2 have short biological half-lives because of rapid enzymatic degradation.

Experimental design may therefore need to account for:

  • Timing of administration
  • Sampling intervals
  • DPP-4 activity
  • Peptide degradation
  • Repeated exposure
  • Continuous infusion
  • Use of stabilized analogs
  • Receptor desensitization
  • Species differences

The use of a DPP-4 inhibitor may extend exposure in certain models, but it may also affect other DPP-4-sensitive peptides and complicate interpretation.

Storage and Handling

GLP-family research peptides are often supplied as lyophilized materials.

Storage requirements depend on the exact peptide, formulation, and supplier documentation.

Researchers should confirm:

  • Long-term storage temperature
  • Appropriate reconstitution solvent
  • Refrigerated stability
  • Freeze-thaw tolerance
  • Adsorption to laboratory plastics
  • Oxidation or aggregation risk
  • Recommended aliquoting procedures

General peptide-storage recommendations should not replace compound-specific stability data.

Research Limitations

Important limitations include:

  • Native GLP peptides are rapidly degraded
  • Animal receptor biology may differ from human biology
  • Long-acting analog data may not apply to native peptides
  • Some tissue-expression claims remain debated
  • Combination studies can be difficult to interpret
  • GLP-3 terminology is not clearly standardized
  • Product labeling may not establish exact peptide identity
  • Research preparations are not equivalent to approved drugs

The GLP-3 section in particular should be regarded as an emerging and uncertain area rather than an established branch of GLP pharmacology.

Conclusion

GLP-1 and GLP-2 are well-characterized proglucagon-derived peptides with distinct but coordinated functions.

GLP-1 is studied primarily for glucose-dependent insulin secretion, glucagon suppression, appetite control, gastric emptying, and metabolic regulation.

GLP-2 is studied primarily for intestinal growth, mucosal repair, barrier integrity, nutrient absorption, and gastrointestinal adaptation.

GLP-3 is far less clearly defined. Its terminology, structure, receptor biology, and physiological role require careful verification before research claims are made.

Together, proglucagon-derived peptides provide an important framework for studying how the intestine communicates with the pancreas, brain, cardiovascular system, and gastrointestinal tissues following nutrient intake.

For research use only. Not intended for human or veterinary use. This article is provided for scientific and educational purposes and does not constitute medical, therapeutic, formulation, or dosing advice.

Continue your research

Explore compounds with clarity.

Review the ECP catalog alongside clear product information and available quality documentation.

Leave a Reply

This product is currently sold out. Don't worry! Enter your email and we'll notify you when it's available again.